- Molecular NameFluphenazine
- SynonymFluorfenazine; Fluorophenazine; Fluorphenazine; Fluphenazine Decanoate; Fluphenazine Hcl; Triflumethazine
- Weight437.53
- Drugbank_IDDB00623
- ACS_NO69-23-8
- Show 2D model
- LogP (experiment)4.36
- LogP (predicted, AB/LogP v2.0)4.36
- pka3.9, 8.1
- LogD (pH=7, predicted)3.44
- Solubility (experiment)0.031.1 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.79
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds7
- TPSA55.25
- StatusFDA approved
- Administrationoral, IM, decanoate
- PharmacologyA typical antipsychotic drug used for the treatment of psychoses such as schizophrenia and acute manic phases of bipolar disorder. It belongs to the piperazine class of phenothiazines and is extremely potent; more potent than haloperidol and around fifty to seventy times the potency of chlorpromazine.
- Absorption_valueN/A
- Absorption (description)The hydrochloride is well absorbed after oral administration
- Caco_2N/A
- Bioavailability2.7
- Protein binding99.0
- Volume of distribution (VD)11 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmFluphenazine is extensively metabolised by sulfoxidation, hydroxylation, and conjugation with glucuronic acid or sulfate. Fluphenazine sulfoxide and 7-hydroxyfluphenazine have been detected in urine and faeces.
- Half life14.4 h
- ExcretionAfter an oral dose of the hydrochloride, 20% is excreted in the urine and 60% is eliminated in the faeces in 7 days; after an IM dose of the enantate, 26% is eliminated in the faeces and 14% excreted in the urine in 14 days; after an IM dose of the decanoate, 17% is eliminated in the faeces and 6% excreted in the urine in 30 days.
- Urinary ExcretionNegligible
- Clerance10 ml/min/kg
- ToxicityAs with other phenothiazine compounds, the side effects most frequently reported with Fluphenazine are extrapyramidal symptoms including pseudo-parkinsonism, dystonia, dyskinesia, akathisia, oculogyric crises, opisthotonos, and hyperreflexia. Most often these extrapyramidal symptoms are reversible; however they may be persistent. The incidence and severity of such reactions depend more on individual patient sensitivity than on other factors, but dosage level and patient age are also determinants.
- LD50 (rat)N/A
- LD50 (mouse)N/A